| 1. |
- Feigin, Valery L., et al.
(författare)
-
Global, regional, and national burden of stroke and its risk factors, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019
- 2021
-
Ingår i: Lancet Neurology. - : Elsevier. - 1474-4422 .- 1474-4465. ; 20:10, s. 795-820
-
Tidskriftsartikel (refereegranskat)abstract
- Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]) associated with 19 risk factors, for 204 countries and territories from 1990 to 2019. These estimates were provided for ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, and all strokes combined, and stratified by sex, age group, and World Bank country income level. Findings In 2019, there were 12.2 million (95% UI 11.0-13.6) incident cases of stroke, 101 million (93.2-111) prevalent cases of stroke, 143 million (133-153) DALYs due to stroke, and 6.55 million (6.00-7.02) deaths from stroke. Globally, stroke remained the second-leading cause of death (11.6% [10.8-12.2] of total deaths) and the third-leading cause of death and disability combined (5.7% [5.1-6.2] of total DALYs) in 2019. From 1990 to 2019, the absolute number of incident strokes increased by 70.0% (67.0-73.0), prevalent strokes increased by 85.0% (83.0-88.0), deaths from stroke increased by 43.0% (31.0-55.0), and DALYs due to stroke increased by 32.0% (22.0-42.0). During the same period, age-standardised rates of stroke incidence decreased by 17.0% (15.0-18.0), mortality decreased by 36.0% (31.0-42.0), prevalence decreased by 6.0% (5.0-7.0), and DALYs decreased by 36.0% (31.0-42.0). However, among people younger than 70 years, prevalence rates increased by 22.0% (21.0-24.0) and incidence rates increased by 15.0% (12.0-18.0). In 2019, the age-standardised stroke-related mortality rate was 3.6 (3.5-3.8) times higher in the World Bank low-income group than in the World Bank high-income group, and the age-standardised stroke-related DALY rate was 3.7 (3.5-3.9) times higher in the low-income group than the high-income group. Ischaemic stroke constituted 62.4% of all incident strokes in 2019 (7.63 million [6.57-8.96]), while intracerebral haemorrhage constituted 27.9% (3.41 million [2.97-3.91]) and subarachnoid haemorrhage constituted 9.7% (1.18 million [1.01-1.39]). In 2019, the five leading risk factors for stroke were high systolic blood pressure (contributing to 79.6 million [67.7-90.8] DALYs or 55.5% [48.2-62.0] of total stroke DALYs), high body-mass index (34.9 million [22.3-48.6] DALYs or 24.3% [15.7-33.2]), high fasting plasma glucose (28.9 million [19.8-41.5] DALYs or 20.2% [13.8-29.1]), ambient particulate matter pollution (28.7 million [23.4-33.4] DALYs or 20.1% [16.6-23.0]), and smoking (25.3 million [22.6-28.2] DALYs or 17.6% [16.4-19.0]). Interpretation The annual number of strokes and deaths due to stroke increased substantially from 1990 to 2019, despite substantial reductions in age-standardised rates, particularly among people older than 70 years. The highest age-standardised stroke-related mortality and DALY rates were in the World Bank low-income group. The fastest-growing risk factor for stroke between 1990 and 2019 was high body-mass index. Without urgent implementation of effective primary prevention strategies, the stroke burden will probably continue to grow across the world, particularly in low-income countries.
|
|
| 2. |
- Micah, Angela E., et al.
(författare)
-
Tracking development assistance for health and for COVID-19 : a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050
- 2021
-
Ingår i: The Lancet. - : Elsevier. - 0140-6736 .- 1474-547X. ; 398:10308, s. 1317-1343
-
Forskningsöversikt (refereegranskat)abstract
- Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$ per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings In 2019, health spending globally reached $8. 8 trillion (95% uncertainty interval [UI] 8.7-8.8) or $1132 (1119-1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total, $40.4 billion (0.5%, 95% UI 0.5-0.5) was development assistance for health provided to low-income and middle-income countries, which made up 24.6% (UI 24.0-25.1) of total spending in low-income countries. We estimate that $54.8 billion in development assistance for health was disbursed in 2020. Of this, $13.7 billion was targeted toward the COVID-19 health response. $12.3 billion was newly committed and $1.4 billion was repurposed from existing health projects. $3.1 billion (22.4%) of the funds focused on country-level coordination and $2.4 billion (17.9%) was for supply chain and logistics. Only $714.4 million (7.7%) of COVID-19 development assistance for health went to Latin America, despite this region reporting 34.3% of total recorded COVID-19 deaths in low-income or middle-income countries in 2020. Spending on health is expected to rise to $1519 (1448-1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.
|
|
| 3. |
- Gangopadhyay, Anjasha, et al.
(författare)
-
Optical studies of two stripped-envelope supernovae – SN 2015ap (Type Ib) and SN 2016P (Type Ic)
- 2020
-
Ingår i: Monthly notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 497:3, s. 3770-3789
-
Tidskriftsartikel (refereegranskat)abstract
- We present the photometric and spectroscopic studies of a Type Ib SN 2015ap and a Type Ic SN 2016P. SN 2015ap is one of the bright (MV = −18.04 mag) Type Ib while SN 2016P lies at an average value among the Type Ic SNe (MV = −17.53 mag). Bolometric light-curve modelling of SNe 2015ap and 2016P indicates that both the SNe are powered by 56Ni + magnetar model with 56Ni masses of 0.01 and 0.002 M⊙, ejecta masses of 3.75 and 4.66 M⊙, spin period P0 of 25.8 and 36.5 ms, and magnetic field Bp of 28.39 × 1014 and 35.3 × 1014 G, respectively. The early spectra of SN 2015ap show prominent lines of He with a ‘W’ feature due to Fe complexes while other lines of Mg ii, Na i, and Si ii are present in both SNe 2015ap and 2016P. Nebular phase [O i] profile indicates an asymmetric profile in SN 2015ap. The [O i]/[Ca ii] ratio and nebular spectral modelling of SN 2015ap hint towards a progenitor mass between 12 and 20 M⊙.
|
|
| 4. |
- Karthic, Anandakrishnan, et al.
(författare)
-
Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp)
- 2022
-
Ingår i: Molecules. - : MDPI AG. - 1420-3049. ; 27:3
-
Tidskriftsartikel (refereegranskat)abstract
- The human population is still facing appalling conditions due to several outbreaks of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) virus. The absence of specific drugs, appropriate vaccines for mutants, and knowledge of potential therapeutic agents makes this situation more difficult. Several 1, 2, 4-triazolo [1, 5-a] pyrimidine (TP)-derivative compounds were comprehensively studied for antiviral activities against RNA polymerase of HIV, HCV, and influenza viruses, and showed immense pharmacological interest. Therefore, TP-derivative compounds can be repurposed against the RNA-dependent RNA polymerase (RdRp) protein of SARS-CoV-2. In this study, a meta-analysis was performed to ensure the genomic variability and stability of the SARS-CoV-2 RdRp protein. The molecular docking of natural and synthetic TP compounds to RdRp and molecular dynamic (MD) simulations were performed to analyse the dynamic behaviour of TP compounds at the active site of the RdRp protein. TP compounds were also docked against other non-structural proteins (NSP1, NSP2, NSP3, NSP5, NSP8, NSP13, and NSP15) of SARS-CoV-2. Furthermore, the inhibition potential of TP compounds was compared with Remdesivir and Favipi-ravir drugs as a positive control. Additionally, TP compounds were analysed for inhibitory activity against SARS-CoV RdRp protein. This study demonstrates that TP analogues (monomethylated triazolopyrimidine and essramycin) represent potential lead molecules for designing an effective inhibitor to control viral replication. Furthermore, in vitro and in vivo studies will strengthen the use of these inhibitors as suitable drug candidates against SARS-CoV-2.
|
|
| 5. |
- Andersson, C. David, 1978-, et al.
(författare)
-
Physical Mechanisms Governing Substituent Effects on Arene-Arene Interactions in a Protein Milieu
- 2020
-
Ingår i: Journal of Physical Chemistry B. - : American Chemical Society (ACS). - 1520-6106 .- 1520-5207. ; 124:30, s. 6529-6539
-
Tidskriftsartikel (refereegranskat)abstract
- Arene-arene interactions play important roles in protein-ligand complex formation. Here, we investigate the characteristics of arene-arene interactions between small organic molecules and aromatic amino acids in protein interiors. The study is based on X-ray crystallographic data and quantum mechanical calculations using the enzyme acetylcholinesterase and selected inhibitory ligands as a model system. It is shown that the arene substituents of the inhibitors dictate the strength of the interaction and the geometry of the resulting complexes. Importantly, the calculated interaction energies correlate well with the measured inhibitor potency. Non-hydrogen substituents strengthened all interaction types in the protein milieu, in keeping with results for benzene dimer model systems. The interaction energies were dispersion-dominated, but substituents that induced local dipole moments increased the electrostatic contribution and thus yielded more strongly bound complexes. These findings provide fundamental insights into the physical mechanisms governing arene-arene interactions in the protein milieu and thus into molecular recognition between proteins and small molecules.
|
|
| 6. |
- Dastidar, R., et al.
(författare)
-
The optical properties of three Type II supernovae : 2014cx, 2014cy, and 2015cz
- 2021
-
Ingår i: Monthly notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 504:1, s. 1009-1028
-
Tidskriftsartikel (refereegranskat)abstract
- We present the photometric and spectroscopic analysis of three Type II supernovae (SNe): 2014cx, 2014cy, and 2015cz. SN 2014cx is a conventional Type IIP with shallow slope (0.2 mag/50 d) and an atypical short plateau (∼86 d). SNe 2014cy and 2015cz show relatively large decline rates (0.88 and 1.64 mag/50 d, respectively) at early times before settling to the plateau phase, unlike the canonical Type IIP/L SN light curves. All of them are normal luminosity SN II with an absolute magnitude at mid-plateau of M50V,14cx=−16.6±0.4mag, M50V,14cy=−16.5±0.2mag, and M50V,15cz=−17.4±0.3mag. A relatively broad range of 56Ni masses is ejected in these explosions (0.027–0.070 M⊙). The spectra shows the classical evolution of SNe II, dominated by a blue continuum with broad H lines at early phases and narrower metal lines with P Cygni profiles during the plateau. High-velocity H i features are identified in the plateau spectra of SN 2014cx at 11 600 kms −1, possibly a sign of ejecta-circumstellar interaction. The spectra of SN 2014cy exhibit strong absorption profile of H i similar to normal luminosity events whereas strong metal lines akin to sub-luminous SNe. The analytical modelling of the bolometric light curve of the three events yields similar progenitor radii within errors (478, 507, and 660 R ⊙ for SNe 2014cx, 2014cy, and 2015cz, respectively), a range of ejecta masses (15.0, 22.2, and 20.6 M ⊙ for SNe 2014cx, 2014cy, and 2015cz), and a modest range of explosion energies (3.3–7.2 foe where 1 foe=10 51erg).
|
|
| 7. |
- Jha, Abhishek Kumar Rajesh, et al.
(författare)
-
Comparison of Methods for Calculating Indirect Upstream Carbon Emissions from Information and Communication Technology Manufacturing
- 2023
-
Ingår i: WSEAS Transactions on Environment and Development. - 1790-5079 .- 2224-3496. ; 19, s. 1045-1057
-
Tidskriftsartikel (refereegranskat)abstract
- The use of Information Communication technology (ICT) is rapidly increasing in an age ofdigitalization. Measurement of carbon dioxide equivalent (CO2e) emissions from ICT is crucial for reducingthem. Most ICT organizations focus on Scope 1 and 2 emissions as they have greater control over them, commonly ignoring Scope 3 emissions. Scope 3 Category 1 (S3C1) emissions occur throughout the rawmaterial acquisition and manufacturing stages of an ICT product's life cycle accounting for a large portion ofthe sector's overall CO2e emissions and energy consumption. By not reporting Scope 3 emissions, companieslose the ability to reduce their overall CO2e corporate emissions. Although Category 1 and 11 under Scope 3account for 85% of ICT's worldwide CO2e emissions, the methodologies for calculating S3C1 emissions in ICTare understudied. This study focuses on these emissions in the framework of Sustainable Development Goals 9,12, and 13. Product life cycle assessment (PLCA) and Spend-based methods have been used to analyze S3C1emissions in the ICT sector with two case examples of laptop computers and smartphones. The ExcelManagement Life Cycle Assessment (EMLCA) tool has been used for the S3C1 emissions estimation. PLCAand Spend-based methods are compared on their ability to calculate CO2e emissions. It is concluded that theSpend-based is faster than PLCA for predicting ICT emissions with modest uncertainty for smartphone andlaptop components. Furthermore, this work explores the advantages and downsides of both methods.
|
|
